Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
What happened
The Food and Drug Administration (FDA) is classifying the "monitor for opioid induced impairment of oxygenation" into class II, designated with special controls. This final order was effective on June 30, 2026, though the classification itself was applicable on March 31, 2023. The action was taken because the FDA determined that class II provides reasonable assurance of safety and effectiveness, and it was signed by Donald Trump.
Why it matters
By placing these medical devices into a lower-risk class, the FDA aims to reduce regulatory burdens for manufacturers. This change is expected to enhance patients' access to beneficial and innovative devices that help detect opioid-induced oxygen impairment. The classification also allows these devices to serve as predicates for future devices, simplifying the approval process for similar innovations.
Who it affects
- ›Patients needing monitoring for opioid impairment
- ›Medical device manufacturers
- ›Healthcare providers and hospitals
- ›FDA regulatory processes
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.